Extremely preterm infants have a significant risk of death or severe intracranial hemorrhage in the first seven days of life.

For six and a half years, staff at the University of Alabama at Birmingham Regional Neonatal Intensive Care Unit (RNICU) planned and instituted a comprehensive, evidence-based quality improvement initiative — now called the Golden Week Program — to reduce that death and severe brain bleeding. The study included 820 extremely preterm infants born at UAB, with an average gestational age of 25 weeks, 3 days and a median weight of 1 pound, 10 ounces.

The results, now published in the journal Pediatrics, was a significant reduction in either death or severe brain bleeding from the baseline rate of 27.4 percent in the 13 months before implementing potentially better practices to 15 percent in the final 27 months of the study. The rate of severe intracranial hemorrhage alone decreased from a baseline rate of 16.4 percent to 10 percent.

Planning began with a comprehensive literature review to develop evidence-based guidelines for the care of these extremely preterm infants, both in UAB’s RNICU and in labor and delivery at the time of birth.

The UAB researchers, led by Dr. Charitharth Vivek Lal, senior author of the Pediatrics study, then introduced multiple evidence-based, potentially better practices — a grouping known as a bundle. In medical care, bundles have helped improve delivery room care and perinatal survival and reduce central line-associated bloodstream infections. Dr. Colm Travers is the first author of the study and was a neonatal fellow when the study began in 2015. Travers led the study execution with Lal.

The comprehensive bundle for interdisciplinary teams in the UAB RNICU included specific electronic order sets to help improve compliance. Changes in care included improved targeting of blood carbon dioxide and pH levels, lower use of medications that change the force of the heart’s contraction, improved adherence to delayed umbilical cord clamping after birth, expanding the prophylactic use of nonsteroidal anti-inflammatory drugs and avoiding sodium bicarbonate administration.

Changes included a twice-daily rounding checklist with a flow chart for ventilator settings, blood gas values, and fluid and electrolyte balances, as well as nurse-led checklists. Other practices included implementation of standardized delivery room practices and, for the first three days of life, maintaining a midline head position for the infant, weighing every 12 hours to help manage fluid and electrolytes, and checking blood sodium levels every 12 hours.

In October 2018, 42 months into the study, the researchers began a Golden Week-specific service, and in January 2019, a dedicated team of Golden Week nurse practitioners began to care for these infants.

“It is possible that some of the potentially better practices we selected may prove ineffective in randomized controlled trials; but by introducing multiple practices, we may have mitigated the problem of implementing ineffective practices,” Lal said. “With this study, we observed improvement in death or severe intracranial hemorrhage in the first week after birth. It is not known whether this will translate into lower rates of death or neurodevelopmental impairment at follow-up, although severity of intracranial hemorrhage predicts later outcomes.”

The UAB RNICU is an academic quaternary referral center with about 1,400 admissions annually, including 130 inborn extremely preterm infants from 22 weeks, 0 days to 27 weeks, 6 days gestation, the gestational range used in the study. Care for the average daily census of 90 infants in the RNICU comes from a staff of more than 350, including nurses, respiratory therapists, pediatric residents, neonatal fellows, neonatal faculty, maternal fetal medicine fellows and maternal fetal medicine faculty.

At UAB, Lal is an associate professor in the UAB Department of Pediatrics, Division of Neonatology and director of the Golden Week Small Baby Program. Travers is an assistant professor in the UAB Department of Pediatrics, Division of Neonatology. Pediatrics is a department in the Marnix E. Heersink School of Medicine.

Co-authors with Lal and Travers in the Pediatrics study, “A quality improvement bundle to improve outcomes in extremely preterm infants in the first week,” are Samuel Gentle, Amelia Freeman, Vivek Shukla, Kalsang Dolma, Lindy Winter, Namasivayam Ambalavanan and Waldemar Carlo, Division of Neonatology, UAB Department of Pediatrics; and Kim Nichols and Donna Purvis, UAB Hospital.

Support came from American Heart Association grant 17SDG32720009, National Institutes of Health grant HL141652, the UAB Perinatal Health and Human Development Research Program, and the UAB Division of Neonatology.

This story originally appeared on the UAB News website.

(Courtesy of Alabama NewsCenter)

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path.

Many infected patients remain asymptomatic or have mild symptoms. Others, especially those with comorbidities, can develop severe clinical disease with atypical pneumonia and multiple system organ failure.

Since the first cases were reported in December 2019, the SARS-CoV-2 virus that causes COVID-19 has surged into a pandemic, with cases and deaths still mounting. Ongoing observational clinical research has become a priority to better understand how this previously unknown virus acts, and findings from this research can better inform treatment and vaccine design.

University of Alabama at Birmingham researchers, led by first-author Jacob “Jake” Files and co-senior authors Nathan Erdmann, M.D., Ph.D., and Paul Goepfert, M.D., have now reported their observational study, “Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection,” published in the Journal of Clinical Investigation. (more…)

Why is the COVID-19 virus more dangerous in people with existing illnesses?

Sadis Matalon, of the University of Alabama at Birmingham, and colleagues in Texas and San Francisco asked that question in a hypothesis paper published online in Physiological Reviews on March 27. They reviewed, in detail, research literature for hypertension, diabetes, coronary heart disease, cerebrovascular illness, chronic obstructive pulmonary disease and kidney dysfunction, as well as many viral studies, studies of COVID-19 pathology and clinical presentation, and literature on the life-threatening acute respiratory distress syndrome. (more…)

Urgent high-impact COVID-19 research at the University of Alabama at Birmingham is catching its second breath, thanks to the generosity of Alabama business leader donors and the discovery and clinical skills of UAB researchers.

Ten new pilot projects — funded by $402,000 in donations — began Aug. 1. The projects will last six months and were selected for their high probability of having an impact on the COVID-19 crisis within weeks or months. Competition for funding was open to the entire university, and 76 applications were received, showing the intense interest of faculty across the campus.

This round of research grants follows 14 projects advertised to faculty of the UAB School of Medicine that were funded beginning May 1, after the Birmingham and Montgomery business community raised $1.1 million in just 20 days in March and April. Part of that money is helping fund this second round. (more…)

Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced positive results from the preclinical studies conducted in mice at the University of Alabama at Birmingham of its intranasal COVID-19 vaccine candidate, AdCOVID.

The studies — a collaboration between UAB and the Gaithersburg, Maryland-based Altimmune — showed strong serum neutralizing activity and potent mucosal IgA immunity in the respiratory tract. The induction of IgA antibody in the respiratory tract may be necessary to block both infection and transmission of the virus to prevent further spread of COVID-19. Based on these findings, AdCOVID is expected to be advanced to a Phase 1 safety and immunogenicity study in Q4 of this year.  (more…)

The University of Alabama at Birmingham will join an international effort coordinated by Scripps Research to test drugs for COVID-19.

The work centers around ReFRAME, a vast collection of drugs developed for other diseases that are already known to be safe for humans. Researchers at Calibr, the drug development division of Scripps Research, are teaming up with scientists from the United States, Europe and Asia to screen this vast collection for individual drugs or combinations that may be effective in treating people exposed to COVID-19.

Rich Whitley, M.D., distinguished professor of pediatrics, will lead the UAB effort. (more…)

The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.

The testing at UAB will investigate immune responses to the vaccine in mice — a key step before the Gaithersburg, Maryland-based Altimmune can launch a Phase 1 human safety and immunogenicity trial in patients in Q3 of this year. The COVID-19 vaccine, called AdCOVID, is a single-dose vaccine candidate that is delivered by an intranasal spray.

Altimmune created AdCOVID in response to the COVID-19 global pandemic. The company has significant experience in the development of intranasal vaccine candidates for respiratory pathogens, including a seasonal and pandemic influenza vaccine and a vaccine for inhalation anthrax. The anthrax vaccine candidate is being developed under a $133.7 million contract with the U.S. Biomedical Advanced Research and Development Authority. (more…)

Beta cells in the pancreas produce insulin. Their death is a key feature of Type 1 diabetes, and that loss starts long before diagnosis. However, there has been no straightforward way to measure that early loss.

Anath Shalev, M.D., and colleagues at the University of Alabama at Birmingham now have identified an early biomarker of Type 1 diabetes-associated beta-cell loss in humans – microRNA-204, or miR-204.

“Serum miR-204,” Shalev said, “may provide a much needed novel approach to assess early Type 1 diabetes-associated human beta-cell loss, even before onset of overt disease.” (more…)

O’Neal Industries Inc., a family-owned global business based in Birmingham, and its shareholders have given the largest single gift in the University of Alabama at Birmingham’s history – a $30 million donation to the Comprehensive Cancer Center. The gift will allow the center to change the lives of more patients and families through transformational cancer research, patient care, education and prevention.

The center will be known as the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham.
(more…)